Copyright
©The Author(s) 2020.
World J Gastroenterol. Jul 28, 2020; 26(28): 4140-4150
Published online Jul 28, 2020. doi: 10.3748/wjg.v26.i28.4140
Published online Jul 28, 2020. doi: 10.3748/wjg.v26.i28.4140
Table 1 Analysis of correlation between insulin receptor substrate 1 expression and clinicopathologic features, n (%)
Clinicopathological features | IRS-1 expression | P Fisher exact test | ||
Weak (0), n = 66 | Strong (1+, 2+), n = 61 | |||
Age (yr) | ≤ 60 (n = 42) | 22 (33.8) | 20 (33.3) | 0.552 |
> 60 (n = 83) | 43 (66.2) | 40 (66.7) | ||
Gender | Male (n = 70) | 37 (56.1) | 33 (54.1) | |
Female (n = 56) | 28 (42.4) | 28 (45.9) | ||
Tumor Localization | Rectum (n = 57) | 33 (50.8) | 24 (39.3) | 0.134 |
Colon (n = 69) | 32 (49.2) | 37 (60.7) | ||
Histological Typea | A (n = 104) | 46 (69.7) | 58 (95.1) | < 0.001 |
MA (n = 23) | 20 (30.3) | 3 (4.9) | ||
Histological differentiationa | G2 (n = 87) | 35 (53.8) | 52 (85.2) | < 0.001 |
G3 (n = 39) | 30 (46.2) | 9 (14.8) | ||
Tumor size | pT1 + pT2 (n = 11) | 7 (10.6) | 4 (6.6) | 0.312 |
pT3 + pT4 (n = 116) | 59 (89.4) | 57 (93.4) | ||
Lymph node Involvement | Negative (n = 60) | 29 (43.9) | 31 (50.8) | 0.438 |
Positive (n = 67) | 37 (56.1) | 30 (49.2) |
Table 2 Analysis of correlations between Insulin receptor substrate 1, Bax and Bcl-xL expressions in primary colorectal cancer
Groups of patients | IRS-1–Bax | IRS-1–Bcl-xL | |||||
n | P value | r | n | P value | r | ||
All | 123 | < 0.001 | 0.513a | 119 | < 0.001 | 0.354a | |
Age (yr) | ≤ 60 | 40 | < 0.001 | 0.661a | 41 | 0.001 | 0.481a |
> 60 | 81 | < 0.001 | 0.424a | 76 | 0.020 | 0.267a | |
Sex | Male | 67 | < 0.001 | 0.497a | 63 | 0.011 | 0.319a |
Female | 55 | < 0.001 | 0.537a | 55 | 0.002 | 0.415a | |
Localization | Rectum | 54 | < 0.001 | 0.460a | 51 | 0.080 | 0.247a |
Colon | 68 | < 0.001 | 0.536a | 67 | < 0.001 | 0.446a | |
HP–type | A | 101 | < 0.001 | 0.535a | 96 | < 0.001 | 0.535a |
MA | 22 | 0.953 | -0.013 | 23 | 0.841 | -0.044 | |
G | G2 | 84 | < 0.001 | 0.523a | 83 | 0.006 | 0.300a |
G3 | 38 | 0.263 | 0.186 | 35 | 0.474 | 0.125 | |
T | pT1 + pT2 | 10 | 0.455 | 0.268 | 11 | 0.005 | 0.772a |
pT3 + pT4 | 113 | < 0.001 | 0.529a | 108 | 0.001 | 0.302a | |
N | pN (-) | 58 | < 0.001 | 0.507a | 57 | 0.007 | 0.351a |
pN (+) | 65 | < 0.001 | 0.493a | 62 | 0.007 | 0.336a |
Table 3 Analysis of correlations between Insulin receptor substrate 1 and Ki-67 expression in primary colorectal cancer
Groups of patients | IRS-1 – Ki-67 | |||
n | P value | r | ||
All | 102 | 0.589 | 0.054 | |
Age (yr) | ≤ 60 | 32 | 0.291 | -0.193 |
> 60 | 68 | 0.147 | 0.178 | |
Sex | Male | 55 | 0.893 | 0.018 |
Female | 46 | 0.517 | 0.098 | |
Localization | Rectum | 45 | 0.662 | -0.067 |
Colon | 56 | 0.285 | 0.145 | |
HP–type | A | 85 | 0.751 | 0.035 |
MA | 17 | 0.239 | -0.302 | |
G | G2 | 71 | 0.845 | 0.024 |
G3 | 30 | 0.714 | 0.070 | |
T | pT1 + pT2 | 8 | 0.043 | 0.723a |
pT3 + pT4 | 94 | 0.973 | -0.004 | |
N | pN (-) | 49 | 0.471 | 0.105 |
pN (+) | 53 | 0.999 | 0.000 |
Table 4 Analysis of correlations between Bax and Bcl-xL expression in primary colorectal cancer
Groups of patients | Bax–Bcl-xL | |||
n | P value | r | ||
All | 115 | < 0.001 | 0.556a | |
Age(yr) | ≤ 60 | 39 | < 0.001 | 0.575a |
> 60 | 74 | < 0.001 | 0.530a | |
Sex | Male | 60 | < 0.001 | 0.453a |
Female | 54 | < 0.001 | 0.643a | |
Localization | Rectum | 48 | < 0.001 | 0.490a |
Colon | 66 | < 0.001 | 0.594a | |
HP–type | A | 93 | < 0.001 | 0.546a |
MA | 22 | 0.013 | 0.519a | |
G | G2 | 80 | < 0.001 | 0.523a |
G3 | 34 | < 0.001 | 0.543a | |
T | pT1 + pT2 | 10 | 0.537 | 0.222 |
pT3 + pT4 | 105 | < 0.001 | 0.577a | |
N | pN (-) | 55 | < 0.001 | 0.509a |
pN (+) | 60 | < 0.001 | 0.582a |
- Citation: Lomperta K, Jakubowska K, Grudzinska M, Kanczuga-Koda L, Wincewicz A, Surmacz E, Sulkowski S, Koda M. Insulin receptor substrate 1 may play divergent roles in human colorectal cancer development and progression. World J Gastroenterol 2020; 26(28): 4140-4150
- URL: https://www.wjgnet.com/1007-9327/full/v26/i28/4140.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i28.4140